Revealing fosfomycin primary effect on Staphylococcus aureus transcriptome: modulation of cell envelope biosynthesis and phosphoenolpyruvate induced starvation
- Marko Petek†1Email author,
- Špela Baebler†1,
- Drago Kuzman2,
- Ana Rotter1,
- Zdravko Podlesek3,
- Kristina Gruden1,
- Maja Ravnikar1 and
- Uroš Urleb2
© Petek et al; licensee BioMed Central Ltd. 2010
Received: 23 December 2009
Accepted: 1 June 2010
Published: 1 June 2010
Staphylococcus aureus is a highly adaptable human pathogen and there is a constant search for effective antibiotics. Fosfomycin is a potent irreversible inhibitor of MurA, an enolpyruvyl transferase that uses phosphoenolpyruvate as substrate. The goal of this study was to identify the pathways and processes primarily affected by fosfomycin at the genome-wide transcriptome level to aid development of new drugs.
S. aureus ATCC 29213 cells were treated with sub-MIC concentrations of fosfomycin and harvested at 10, 20 and 40 minutes after treatment. S. aureus GeneChip statistical data analysis was complemented by gene set enrichment analysis. A visualization tool for mapping gene expression data into biological pathways was developed in order to identify the metabolic processes affected by fosfomycin. We have shown that the number of significantly differentially expressed genes in treated cultures increased with time and with increasing fosfomycin concentration. The target pathway - peptidoglycan biosynthesis - was upregulated following fosfomycin treatment. Modulation of transport processes, cofactor biosynthesis, energy metabolism and nucleic acid biosynthesis was also observed.
Several pathways and genes downregulated by fosfomycin have been identified, in contrast to previously described cell wall active antibiotics, and was explained by starvation response induced by phosphoenolpyruvate accumulation. Transcriptomic profiling, in combination with meta-analysis, has been shown to be a valuable tool in determining bacterial response to a specific antibiotic.
Staphylococcus aureus is a common human pathogen. It is known to be highly adaptable, as shown in the rapid development of resistance to most known antibiotics. Much research in the last decade has been devoted to discovering new broad-spectrum antibiotic agents. A large proportion of effective antibiotics act on the cell wall which has been taken as an adequate target in the development of new drugs. Most cell wall active antibiotics in clinical use, for example β-lactams and glycopeptides, act by inhibiting late steps of peptidoglycan synthesis on the outer side of the cell membrane. The enzymes that catalyze the intracellular part of the peptidoglycan synthesis pathway, muramyl peptide ligases (Mur enzymes), are also good candidates for antibiotic drug targeting, because human cells do not synthesize similar enzymes. Inhibition of these enzymes causes substantial impairment of bacterial cell wall biosynthesis which, at higher doses of inhibitor, leads to decreased cell growth and to cell lysis. However, only two antibiotic agents targeting Mur enzymes are in clinical use, fosfomycin and cycloserine. Fosfomycin is a potent irreversible inhibitor of MurA, an enolpyruvyl transferase that catalyses the condensation of uridine diphosphate-N-acetylglucosamine with phosphoenolpyruvate (PEP) . This reaction is the first step in the peptidoglycan biosynthesis pathway.
Genome-scale expression profiling, using microarray technology, can be used to determine potential drug targets . The Staphylococcus aureus microarray meta-database (SAMMD, ) contains sets of differentially expressed genes, identified by published S. aureus expression profiling experiments. This database simplifies comparison of experimental data and provides a quick overview of published experiments for this bacterium.
Our goal is to develop a platform for transcriptional profiling of new Mur ligase inhibitors. As a reference, the transcription profile was determined for the well characterized inhibitor of MurA ligase, fosfomycin. We have focused on the pathways and processes primarily affected by fosfomycin. In contrast to other genome-wide profiling studies of pathogen responses to antimicrobial substances, we have studied the response to low concentrations of antimicrobial agent early after its addition. An innovative data analysis approach, complemented by newly devised visualization tools, pathway analysis and meta-analysis of similar experiments, enabled us to identify differentially expressed gene groups and pathways, and to conclude that the response of the bacterium to fosfomycin is not only time but also concentration dependent.
Results and discussion
Time and concentration dependent effects of fosfomycin
The concentration dependence of the transcriptome response was also observed at the individual gene level. For example, alanine racemase gene SA1231, some transporter genes (opp2B, SA1183, SA1972, msmX, SA0207, malF) and amino acid biosynthesis genes dhoM and hisC were significantly differentially expressed only at higher concentrations of fosfomycin (see Additional file 1).
Metabolic pathways affected by fosfomycin treatment
Analysis of gene groups and metabolic pathways is suitable for biological interpretation of microarray analysis results, where grouping is essential to retain the overview. We have chosen TIGRFAM functional classification to group S. aureus genes by the known or predicted biochemical role of the protein they encode. The greatest proportion of differentially expressed genes belong to the groups "cell envelope", "transport and binding proteins" and "energy metabolism", indicating that these were the processes affected most by fosfomycin (Figure 3). A global transcriptional response became evident after 20 min of incubation. Interestingly, mainly the same processes were affected at both concentrations.
Enriched gene sets after 10, 20 and 40 minutes of treatment with fosfomycin.
AMINO ACID BIOSYNTHESIS_ASPARTATE FAMILY
AMINO ACID BIOSYNTHESIS_OTHER
TRANSPORT AND BINDING PROTEINS_AMINO ACIDS, PEPTIDES AND AMINES
TRANSPORT AND BINDING PROTEINS_CARBOHYDRATES, ORGANIC ALCOHOLS, AND ACIDS
TRANSPORT AND BINDING PROTEINS_CATIONS AND IRON CARRYING COMPOUNDS
TRANSPORT AND BINDING PROTEINS_UNKNOWN SUBSTRATE
ENERGY METABOLISM_AMINO ACIDS AND AMINES
ENERGY METABOLISM_ATP-PROTON MOTIVE FORCE INTERCONVERSION, BIOSYNTHESIS AND DEGRADATION OF POLYSACCHARIDES, PYRUVATE DEHYDROGENASE
ENERGY METABOLISM_SUGARS AND TCA CYCLE
CELL ENVELOPE_BIOSYNTHESIS AND DEGRADATION OF MUREIN SACCULUS AND PEPTIDOGLYCAN
CELL ENVELOPE_BIOSYNTHESIS AND DEGRADATION OF SURFACE POLYSACCHARIDES AND LIPOPOLYSACCHARIDES
CELLULAR PROCESSES_CELL DIVISION
CELLULAR PROCESSES_TOXIN PRODUCTION AND RESISTANCE
CENTRAL INTERMEDIARY METABOLISM_NITROGEN METABOLISM AND AMINO SUGARS
CENTRAL INTERMEDIARY METABOLISM_OTHER
PURINES, PYRIMIDINES, NUCLEOSIDES, AND NUCLEOTIDES
PROTEIN SYNTHESIS_TRNA AMINOACYLATION
PROTEIN FATE_DEGRADATION OF PROTEINS, PEPTIDES, AND GLYCOPEPTIDES
PROTEIN FATE_PROTEIN AND PEPTIDE SECRETION AND TRAFFICKING
PROTEIN FATE_PROTEIN MODIFICATION AND REPAIR_PROTEIN FOLDING AND STABILIZATION
PROTEIN SYNTHESIS_RIBOSOMAL PROTEINS: SYNTHESIS AND MODIFICATION_TRANSLATION FACTORS
PROTEIN SYNTHESIS_TRNA AND RRNA BASE MODIFICATION
Cell envelope synthesis is strongly affected by fosfomycin treatment
The GSEA results showed that specific subgroups of genes in the cell envelope group were regulated differently (Table 1). Genes involved in murein and peptidoglycan biosynthesis, including teichoic acid biosynthesis genes, were upregulated, while surface polysaccharide metabolism genes were downregulated.
To interpret the changes in gene expression we visualized the data in Pathway Studio software. Since the peptidoglycan biosynthesis pathway is not complete in the existing metabolic network , the pathway was complemented with literature data. The .gpc file (Additional file 2) can be used by the scientific comunity to interpret gene expression data, enabling ready visual comparison of experimental results from different studies.
Autolysin coding genes atl, lytH, SA0423, and SA2100 were downregulated at t40c4, whereas lytM was upregulated by fosfomycin at that point (Figure 5) suggesting the prevention of further degradation of peptidoglycan. As well as in cell wall stress, gene atl has been found to be downregulated in acid shock , SOS response and, cold shock, but upregulated in stringent response .
Expression of "cell wall stress stimulon" genes: comparison of current study with published results in the SAMMD.
N315 LOCUS a
Gene Name b
Expression fold change c
Gene Product Description e
TIGR Functional Group
Cell wall active antibiotics d
Fmt, autolysis and methicillin resistant-related protein
hypothetical protein, similar to serine proteinase
peptidyl-prolyl cis/trans isomerase homolog
hypothetical protein, similar to penicillin-binding protein 1A/1B
two-component sensor histidine kinase
conserved hypothetical protein
conserved hypothetical protein
UDP-N-acetylglucosamine 1-carboxylvinyl transferase 2
hypothetical protein, similar to lyt divergon expression
hypothetical protein, similar to GTP-pyrophosphokinase
hypothetical protein, similar to autolysin (N-acetylmuramoyl-L-alanine amidase)
A transcriptional response specific to MurA inhibition
In order to reach target enzymes MurA and MurZ, fosfomycin has to cross the cell membrane. Because of its hydrophilic nature it uses the active transport systems (ABC transport proteins), specifically the L-α-glycerophosphate and the glucose-6-phosphate uptake systems . The PEP phosphotransferase system (PTS) mediates the uptake and phosphorylation of carbohydrates and controls metabolism in response to carbohydrate availability, and can therefore affect the whole cell metabolic rate . GSEA shows that PTS was downregulated by fosfomycin 20 and 40 minutes after treatment. This downregulation could be a defense mechanism against the influx of fosfomycin. It has been reported that PTS mutant bacteria are highly resistant to fosfomycin  and that some fosfomycin-resistant E. coli isolates have altered glpT and/or uhp transport systems . The downregulation of PTS genes can also contribute to PEP accumulation . As shown in Figure 3 and Table 1, transport processes in general were significantly downregulated. The majority of differentially expressed genes in this group encode proteins that transport oligopeptides (opp genes), amino acids, sugars, polyamines (potABCD) and cations into the cell. Genes encoding iron transport and binding proteins, belonging to the Isd system, were also downregulated similarly as in a MurF underexpression mutant study . However, a small proportion of transport genes were upregulated, including some amino acid and oligopeptide carrier genes and the sodium/hydrogen exchanger genes mnhBCDEG.
The energy metabolism group, consisting of genes involved in sugar metabolism, amino acid degradation and TCA cycle, were generally downregulated (Figure 3), consistent with a starvation response. The downregulated amino acid metabolism genes include met and dap operons; additionally, the aspartate family was shown to be significantly downregulated by GSEA (Table 1). Upregulated amino acid metabolism genes include genes involved in cysteine biosynthesis and synthesis of cystathionine. Various tRNA synthetases, probably connected to amino acid biosynthesis, were also downregulated.
Strong downregulation of virulence genes by fosfomycin was observed, especially 40 min after treatment. These genes include hla, spa, aur, sspABC and 16 cap genes (capA - capF) encoding capsular polysaccharide synthesis enzymes. Capsular genes were also downregulated in the SOS response , but upregulated by cycloserine treatment , sigB mutant  and biofilm forming S. aureus . It has been shown that cap genes and various virulence factors are regulated by Sae and Agr global regulatory proteins. It was shown that Agr causes induction, and Sae repression, of cap genes [19, 20], but in our experiments none of these regulatory genes were differentially expressed.
A pathway-based approach enabled us to determine that the response of S. aureus to fosfomycin is not only time but also concentration dependent, and that the major transcriptional switch occurred after 20 to 40 min of treatment. The fosfomycin response was similar to those of other cell-wall-active antibiotics in the cell envelope pathway and the cell wall stress stimulon genes. However, in contrast to previously described cell-wall-active antibiotic treatments, we have identified several pathways and genes downregulated by fosfomycin, such as transport, nucleic acid biosynthesis, energy metabolism and virulence genes. The downregulation of these pathways was explained by a starvation response induced by PEP accumulation. We have shown that transcriptomic profiling, in combination with meta-analysis, is a valuable tool in determining bacterial response to a specific antibiotic.
Bacterial growth conditions
Staphylococcus aureus, strain ATCC 29213 was cultured in a small volume of cation-adjusted Mueller-Hinton broth medium (Sigma-Aldrich) and grown in Erlenmeyer flask on a gyratory shaker (200 rpm) at 37°C. The overnight culture was diluted 100-fold in 300 ml of medium and grown under the same conditions in 1-L Erlenmeyer flasks until OD600 reached 0.3, which corresponded to the early exponential stage of growth.
With the potential of testing new chemical entities in mind, the experiment was designed to allow substances slightly soluble in water to be tested. Fosfomycin (Sigma) was diluted in DMSO (Sigma) to give final concentrations of 5% DMSO with 1 (c1) and 4 (c4) μg/ml of fosfomycin. DMSO alone was added to the control cultures (c0), to normalize the effects of DMSO treatment.
Appropriate fosfomycin concentrations were determined in a preliminary growth study (data not shown). Growth rate (measured as OD) and proportion of live cells determined with the LIVE/DEAD BacLight™ Bacterial Viability Kit (Invitrogen) were monitored for a range of concentrations from 1 to 1024 μg/ml. For the microarray experiments concentrations were selected that did not affect bacterial growth in the first few hours after treatment. The experiment was repeated four times, from four independently grown bacterial inoculates, thus yielding 40 samples.
Sampling and RNA preparation
The bacterial culture (prepared as described above) was divided into 10 flasks (19 ml per flask) containing previously prepared fosfomycin solutions. Cultures were grown as described above and sampled (7 ml per flask) at the time of treatment (t0) and 10 (t10), 20 (t20) and 40 minutes (t40) after treatment. The OD of each culture was measured immediately before sampling (data not shown) and the cultures were stabilized using RNAprotect Bacteria Reagent (Qiagen), following the manufacturers protocol. The bacterial pellets were stored at -80°C.
RNA was isolated from bacterial pellets by enzymatic cell wall lysis  followed by RNeasy Mini Kit (Qiagen) purification. Two hundred μl of lysis buffer (20 mM TRIS HCl, 50 mM EDTA, 200 g/l sucrose, pH 7.0), containing lysostaphin (Sigma; 15 μg/μL) was added to the cell pellet and incubated on ice for 20 minutes. The lysate was transferred to a water bath at 37°C for 3 minutes. After incubation, 200 μl of 2% SDS and 7 μl of proteinase K were added and the lysate incubated at room temperature for 15 minutes. 800 μl of the RLT buffer (from RNeasy Kit) was added to the lysate, vortexed vigorously and sonicated for 5 minutes at 56°C. After the addition of 600 μl of absolute ethanol, the lysate was transferred to the RNeasy Mini columns and centrifuged until all the lysate was used. The remaining steps were as described in RNeasy Mini Kit manufacturer's protocol. The elution was performed twice with pre-heated (60°C) water and 5 minutes incubation time. To remove remaining genomic DNA, total RNA samples were treated with DNase I (Deoxyribonuclease I, amplification grade, Invitrogen), as recommended by manufacturer, only with lower optimized DNase concentration of 0.25 U per μg of total RNA. The RNA was purified and concentrated using RNeasy Min Elute Kit (Qiagen). Finally the RNA was checked for quality and quantity using absorbance measurements (Nanodrop) and agarose gel electrophoresis (data not shown). Two samples did not meet the quality demands and were not used for microarray hybridization.
RNA was labelled and hybridized to GeneChip® S. aureus Genome Arrays (Affymetrix) according to the GeneChip® Expression Analysis Technical Manual, the section for prokaryotic antisense arrays. Targets were prepared by cDNA synthesis with random primers, RNA degradation, cDNA purification and fragmentation, followed by terminal labelling with biotin. Labelled cDNA was hybridized on the microarrays, which were subsequently washed, stained and scanned.
Quality control and statistical data analysis
Data was analysed with bioconductor (R version 2.10.0; http://www.bioconductor.org) packages affy , gcrma  and limma . Quality control of the microarray consisted of visual inspection of various diagnostic plots, namely boxplots of transcript intensities, image plots of arrays and MA plots of raw data. Additionally, parameters from the Affymetrix software were evaluated. Moreover, RLE (Relative Log Expression) and NUSE (Normalized Unscaled Standard Error) plots were constructed . Of 38 analyzed arrays, one did not meet the quality requirements and was therefore excluded from further analysis.
Data pre-processing and expression value calculation were carried out using two procedures, yielding 2 separate datasets. In the first, a combination of rma convolution method for background adjustment , invariantset for normalization , pm correction as from the mas manual, and liwong method summarization [27, 28] were applied. In the second procedure, all the pre-processing steps were performed simultaneously using gcrma .
In order to find differentially expressed genes a statistical model was formulated (p < 0.05) to compare gene expression in bacteria exposed to fosfomycin concentrations c1 and c4 with that of the control (c0) at a given time point. To decrease false discovery rate, the results coming from different pre-processing procedures were combined and only the intersection of genes, differentially expressed following both procedures were taken into account for the biological interpretation of the results .
Biochemical reactions from S. aureus metabolic network reconstruction i SB619  were obtained from BIGG database http://bigg.ucsd.edu/ and coupled with TIGR S. aureus annotation  downloaded from TIGR CMR database http://cmr.tigr.org/tigr-scripts/CMR/CmrHomePage.cgi. Pathway database and expression profiles for all experimental time points were imported to Pathway Studio software (version 4.0; Ariadne Genomics Inc). Differentially expressed genes were queried for presence in metabolic network. Pathways constructed in Pathway Studio were examined and interpreted manually. Pathway Studio .gpc file is available as Additional file 2.
Gene set enrichment analysis (GSEA)  was applied to search for groups of genes involved in the same processes (gene sets) that were altered significantly by fosfomycin treatment. Individual GSEA was performed for a data set including control and both fosfomycin treatment concentrations (1 and 4 μg/ml) for the selected time point. Gcrma-normalized data was filtered for signal intensity greater than 10. The signal intensities from the same time point were overlapped on 40 gene sets (see Additional file 3) based on TIGR S. aureus annotation  and measured for the enrichment of genes at the top or bottom of the gene list to determine their correlation with the logarithm of fosfomycin concentration (gene set's phenotype). The GSEA parameters used included: Pearson metric and gene set size restrictions, 10 minimum, 500 maximum. Gene sets significantly modified by fosfomycin treatment were identified using a multiple hypothesis testing FDR < 0.25. GSEA was performed for each time point (10, 20 and 40 min) at which gene expression was correlated with fosfomycin concentration. Positive correlation was interpreted as up-regulation of a gene set resulting from drug treatment; a negative correlation was interpreted as down-regulation.
Meta-analysis: integration of gene expression data from other sources
Our experimental data was compared to other publicly available S. aureus transcriptomic data. To ease the comparison, the recently published "Staphylococcus aureus microarray meta-database" (SAMMD) was used . The qualitative transcriptional profiles (up or downregulation) were coupled with the quantitative transcriptional profile of fosfomycin to a single spreadsheet (Additional file 1) in order to analyze the similarities and differences between different responses.
Quantitative real-time PCR (qPCR)
Primer and probe sequences used for qPCR analysis.
Data were analyzed using the LightCycler® 480 184.108.40.206 Software. The 2nd derivate method was used for all amplicons to determine Cp values. The standard curve method was used for relative gene expression quantification, and the transcript accumulation of each gene was normalized to 16S rRNA. The amplification efficiency and linear range of amplification were followed for each amplicon on each plate by analyzing a reference sample pool in four dilution steps of cDNA with two replicate wells per dilution step. Each sample was analyzed in two dilutions and two replicates per dilution step. Only samples where the ΔCp between two dilutions of target gene did not deviate by more than 0.5 from ΔCp of the reference gene were used for relative quantification. The fold changes for each experimental point were calculated as a quotient of average transcript abundances between treated and control samples from three independent biological replicates in each time point.
Microarray dataset accession number
Microarray data analyzed in this study have been deposited in the Gene Expression Omnibus database with accession number GSE15394.
The authors would like to acknowledge Dr Ron Peterson (Novartis Institutes for BioMedical Research) for help with microarray hybridizations and Dr Roger Pain for language revision. The work was supported by Slovenian Research Agency (Grant Nos. P4-0165 and Z4-9697), the European Union FP6 Integrated Project EUR-INTAFAR (Project No. LSHM-CT-2004-512138) under the thematic priority Life Sciences, Genomics and Biotechnology for Health and Lek Pharmaceuticals d.d.
- El Zoeiby A, Sanschagrin F, Levesque RC: Structure and function of the Mur enzymes: development of novel inhibitors. Mol Microbiol. 2003, 47 (1): 1-12. 10.1046/j.1365-2958.2003.03289.x.View ArticlePubMed
- Freiberg C, Brotz-Oesterhelt H, Labischinski H: The impact of transcriptome and proteome analyses on antibiotic drug discovery. Curr Opin Microbiol. 2004, 7 (5): 451-459. 10.1016/j.mib.2004.08.010.View ArticlePubMed
- Nagarajan V, Elasri MO: SAMMD: Staphylococcus aureus microarray meta-database. BMC Genomics. 2007, 8: 351-10.1186/1471-2164-8-351.PubMed CentralView ArticlePubMed
- Becker SA, Palsson BO: Genome-scale reconstruction of the metabolic network in Staphylococcus aureus N315: an initial draft to the two-dimensional annotation. BMC Microbiol. 2005, 5 (1): 8-10.1186/1471-2180-5-8.PubMed CentralView ArticlePubMed
- Du W, Brown JR, Sylvester DR, Huang J, Chalker AF, So CY, Holmes DJ, Payne DJ, Wallis NG: Two active forms of UDP-N-acetylglucosamine enolpyruvyl transferase in gram-positive bacteria. J Bacteriol. 2000, 182 (15): 4146-4152. 10.1128/JB.182.15.4146-4152.2000.PubMed CentralView ArticlePubMed
- Sobral RG, Jones AE, Des Etages SG, Dougherty TJ, Peitzsch RM, Gaasterland T, Ludovice AM, de Lencastre H, Tomasz A: Extensive and genome-wide changes in the transcription profile of Staphylococcus aureus induced by modulating the transcription of the cell wall synthesis gene murF. Journal of bacteriology. 2007, 189 (6): 2376-2391. 10.1128/JB.01439-06.PubMed CentralView ArticlePubMed
- Bore E, Langsrud S, Langsrud O, Rode TM, Holck A: Acid-shock responses in Staphylococcus aureus investigated by global gene expression analysis. Microbiology. 2007, 153 (Pt 7): 2289-2303. 10.1099/mic.0.2007/005942-0.View ArticlePubMed
- Anderson KL, Roberts C, Disz T, Vonstein V, Hwang K, Overbeek R, Olson PD, Projan SJ, Dunman PM: Characterization of the Staphylococcus aureus heat shock, cold shock, stringent, and SOS responses and their effects on log-phase mRNA turnover. J Bacteriol. 2006, 188 (19): 6739-6756. 10.1128/JB.00609-06.PubMed CentralView ArticlePubMed
- Utaida S, Dunman PM, Macapagal D, Murphy E, Projan SJ, Singh VK, Jayaswal RK, Wilkinson BJ: Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology (Reading, England). 2003, 149 (Pt 10): 2719-2732.View Article
- Kuroda M, Kuroda H, Oshima T, Takeuchi F, Mori H, Hiramatsu K: Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Molecular microbiology. 2003, 49 (3): 807-821. 10.1046/j.1365-2958.2003.03599.x.View ArticlePubMed
- Cirz RT, Jones MB, Gingles NA, Minogue TD, Jarrahi B, Peterson SN, Romesberg FE: Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin. J Bacteriol. 2007, 189 (2): 531-539. 10.1128/JB.01464-06.PubMed CentralView ArticlePubMed
- Jang HJ, Chang MW, Toghrol F, Bentley WE: Microarray analysis of toxicogenomic effects of triclosan on Staphylococcus aureus. Appl Microbiol Biotechnol. 2008, 78 (4): 695-707. 10.1007/s00253-008-1349-x.View ArticlePubMed
- Brauer MJ, Yuan J, Bennett BD, Lu W, Kimball E, Botstein D, Rabinowitz JD: Conservation of the metabolomic response to starvation across two divergent microbes. Proceedings of the National Academy of Sciences of the United States of America. 2006, 103 (51): 19302-19307. 10.1073/pnas.0609508103.PubMed CentralView ArticlePubMed
- Deutscher J, Francke C, Postma PW: How phosphotransferase system-related protein phosphorylation regulates carbohydrate metabolism in bacteria. Microbiol Mol Biol Rev. 2006, 70 (4): 939-1031. 10.1128/MMBR.00024-06.PubMed CentralView ArticlePubMed
- Cordaro JC, Melton T, Stratis JP, Atagun M, Gladding C, Hartman PE, Roseman S: Fosfomycin resistance: selection method for internal and extended deletions of the phosphoenolpyruvate:sugar phosphotransferase genes of Salmonella typhimurium. J Bacteriol. 1976, 128 (3): 785-793.PubMed CentralPubMed
- Horii T, Kimura T, Sato K, Shibayama K, Ohta M: Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26. Antimicrob Agents Chemother. 1999, 43 (4): 789-793.PubMed CentralPubMed
- Bischoff M, Dunman P, Kormanec J, Macapagal D, Murphy E, Mounts W, Berger-Bachi B, Projan S: Microarray-based analysis of the Staphylococcus aureus sigmaB regulon. J Bacteriol. 2004, 186 (13): 4085-4099. 10.1128/JB.186.13.4085-4099.2004.PubMed CentralView ArticlePubMed
- Beenken KE, Dunman PM, McAleese F, Macapagal D, Murphy E, Projan SJ, Blevins JS, Smeltzer MS: Global gene expression in Staphylococcus aureus biofilms. J Bacteriol. 2004, 186 (14): 4665-4684. 10.1128/JB.186.14.4665-4684.2004.PubMed CentralView ArticlePubMed
- Luong T, Sau S, Gomez M, Lee JC, Lee CY: Regulation of Staphylococcus aureus capsular polysaccharide expression by agr and sarA. Infect Immun. 2002, 70 (2): 444-450. 10.1128/IAI.70.2.444-450.2002.PubMed CentralView ArticlePubMed
- Steinhuber A, Goerke C, Bayer MG, Doring G, Wolz C: Molecular architecture of the regulatory locus sae of Staphylococcus aureus and its impact on expression of virulence factors. J Bacteriol. 2003, 185 (21): 6278-6286. 10.1128/JB.185.21.6278-6286.2003.PubMed CentralView ArticlePubMed
- Kornblum JS, Projan SJ, Moghazeh SL, Novick RP: A rapid method to quantitate non-labeled RNA species in bacterial cells. Gene. 1988, 63 (1): 75-85. 10.1016/0378-1119(88)90547-1.View ArticlePubMed
- Gautier L, Cope L, Bolstad BM, Irizarry RA: affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004, 20 (3): 307-315. 10.1093/bioinformatics/btg405.View ArticlePubMed
- Wu C, Irizarry R, Macdonald J, Gentry J: gcrma:Background Adjustment Using Sequence Information. R package version 2100. 2005
- Smyth GK: limma: Linear Models for Microarray Data. Bioinformatics and computational biology solutions using R and Bioconductor. Edited by: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W. London: Springer, 2005: 397-420.
- Bolstad BM, Collin F, Brettschneider J, Simpson K, Irizarry RA, Speed TP: Quality assessment of Affymetrix GeneChip data. Bioinformatics and computational biology solutions using R and Bioconductor. Edited by: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W. New York: Springer, 2005: 33-47.
- Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003, 4 (2): 249-264. 10.1093/biostatistics/4.2.249.View ArticlePubMed
- Li C, Hung Wong W: Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol. 2001, 2 (8): research0032.0031-0032.0011.
- Li C, Wong WH: Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA. 2001, 98 (1): 31-36. 10.1073/pnas.011404098.PubMed CentralView ArticlePubMed
- Rotter A, Hren M, Baebler S, Blejec A, Gruden K: Finding differentially expressed genes in two-channel DNA microarray datasets: how to increase reliability of data preprocessing. OMICS. 2008, 12 (3): 171-182. 10.1089/omi.2008.0032.PubMed CentralView ArticlePubMed
- Peterson JD, Umayam LA, Dickinson T, Hickey EK, White O: The Comprehensive Microbial Resource. Nucleic Acids Res. 2001, 29 (1): 123-125. 10.1093/nar/29.1.123.PubMed CentralView ArticlePubMed
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005, 102 (43): 15545-15550. 10.1073/pnas.0506580102.PubMed CentralView ArticlePubMed
- McAleese F, Petersen P, Ruzin A, Dunman PM, Murphy E, Projan SJ, Bradford PA: A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrobial agents and chemotherapy. 2005, 49 (5): 1865-1871. 10.1128/AAC.49.5.1865-1871.2005.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.